Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized,Double-blind,Placebo,Positive-controlled Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis

NCT06726096 is registered in ClinicalTrials.gov with Beijing VDJBio Co., LTD. as lead sponsor.

NCT NCT06726096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized,Double-blind,Placebo,Positive-controlled Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
Lead sponsor
Beijing VDJBio Co., LTD.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 9, 2025
Completion date
December 31, 2026
Enrollment
615 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti il-6r, rheumatoid arthritis (ra)